Iceland vs Switzerland: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Iceland
92.0%
in 2025
Switzerland
92.0%
in 2025
Iceland rank
54th
Switzerland rank
54th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Iceland
- Switzerland
How they compare
Iceland currently reports 92.0% against 92.0% in Switzerland, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Switzerland ahead.
Iceland ranks 54th and Switzerland ranks 54th of 192 countries.
Across the 3 decades both report, Iceland averaged higher in 1 and Switzerland in 1.
Head to head by decade
| Decade | Iceland | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 19.0% | 19.0% | Switzerland |
| 2010s | 71.6% | 71.6% | 0.0% | — |
| 2020s | 91.0% | 89.2% | 1.8% | Iceland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Iceland or Switzerland?
- Iceland, at 92.0% against 92.0% in Switzerland as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Iceland and Switzerland?
- 0.0%, with Iceland ahead.
- How many years of comparable data are there for Iceland and Switzerland?
- 18 years are reported by both, from 2008 to 2025.
- How do Iceland and Switzerland rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iceland ranks 54th and Switzerland ranks 54th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.